Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | CCR8 | P51685 | 2/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28071626 | 0.80 | FGFR4 (0.35) | ALDH1A1CCR1NOS2 | |
| SCHEMBL28224216 | 0.77 | ALDH1A1 (0.37) | ALDH1A1CCR1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1153566 | 0.76 | KDM4E (0.46) | ALDH1A1CCR1CCR5CCR8KDM4E | |
| SCHEMBL1153563 | 0.76 | KDM4E (0.46) | ALDH1A1CCR1CCR5CCR8KDM4E | |
| SCHEMBL29955053 | 0.74 | APP (0.39) | ALDH1A1CCR1MAPTTERTKDM4E | |
| SCHEMBL990416 | 0.73 | GRM4 (0.63) | ALDH1A1MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL990418 | 0.73 | GRM4 (0.63) | ALDH1A1MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1717209 | 0.72 | — | — | |
| SCHEMBL1208300 | 0.72 | CCR1 (0.55) | ALDH1A1CCR1MAPTCCR5CCR8 | |
| SCHEMBL29601133 | 0.72 | CCR1 (0.55) | ALDH1A1CCR1MAPTCCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| CN-101426503-A | Compositions and methods of treatment for inhibiting kinase and/or HMG-COA reductase | PHARMIX CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-6251914-B1 | TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-06-26 | — | — | US | disclosed |
| US-6214844-B1 | ANTIARTHRITIC AGENTS; BONE DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |
| EP-1019396-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SmithKline Beecham Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0935465-A4 | — | — | 1999-08-18 | — | — | EP | disclosed |
| EP-0935465-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-18 | — | — | EP | disclosed |
| CN-1213307-A | Novel substituted imidazolium compounds | SMITHKLINE BEECHAM CORP (US) | 1999-04-07 | — | — | CN | disclosed |
| WO-1999001452-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5811549-A | Process of preparing imidazole compounds | SMITHKLINE BEECHAM (US) | 1998-09-22 | — | — | US | disclosed |
| US-5716955-A | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997025046-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | ALDH1A1 3889/4885CCR1 4190/4885MAPT 384/4885 |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | ALDH1A1 1658/4885CCR1 1094/4885MAPT 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.